Journals / Medeniyet Medical Journal / 2020 / Cilt: 35 - Sayı: 4

MODY Probability Ratios in Patients Diagnosed with Type 2 Diabetes Mellitus at a Young Age

Genç Yaşta Tip 2 Diabetes Mellitus Tanısı Almış Hastalarda MODY Olasılık Oranları

Pages
290–294
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this study, we aimedto evaluate whether (MODY Probability Calculator [MPC]) which is one of the screening tests will be helpful inidentifying our high-risk patients among young patients with type 2 diabetesMethod: The patients received the diagnosis of type 2 diabetes aged 20%, the age of onset of diabetes and the body mass index wassignificantly lower than the others (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Maturity-onset diabetes of the young (MODY) is a non-rare group of monogenic inherited diabeteswhich is commonly confused with type 1 and type 2 diabetes.
📊
Key Findings & Data:Due to high costs of genetic tests that provide adefinitive diagnosis, some screening scales are used to identify the high-risk patients.
💡
Conclusion & Impact:In this study, we aimedto evaluate whether (MODY Probability Calculator [MPC]) which is one of the screening tests will be helpful inidentifying our high-risk patients among young patients with type 2 diabetesMethod: The patients received the diagnosis of type 2 diabetes aged 20%, the age of onset of diabetes and the body mass index wassignificantly lower than the others (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Maturity-onset diabetes of the young (MODY) is a non-rare group of monogenic inherited diabeteswhich is commonly confused with type 1 and type 2 diabetes. Due to high costs of genetic tests that provide adefinitive diagnosis, some screening scales are used to identify the high-risk patients. In this study, we aimedto evaluate whether (MODY Probability Calculator [MPC]) which is one of the screening tests will be helpful inidentifying our high-risk patients among young patients with type 2 diabetesMethod: The patients received the diagnosis of type 2 diabetes aged 20%, the age of onset of diabetes and the body mass index wassignificantly lower than the others (p

Özet

Amaç: Gençlerde görülen erişkin tip diyabet (MODY), tip 1 ve tip 2 diyabetle karışan, monogenik geçişli, diyabetin nadir olmayan bir grubunu oluşturmaktadır. Kesin tanıyı sağlayan genetik testlerin maliyetlerinin yüksek olması nedeniyle yüksek riskli hastaları belirlemeye yönelik bazı tarama ölçekleri kullanılmaktadır. Biz bu çalışmamızda diyabet polikliniğine başvuran erken yaş tip 2 diyabet olgularında tarama testlerinden biri olan MODY Olasılık Hesaplayıcısının (MODY Probability Calculator [MPC]) yüksek riskli hastalarımızın belirlenmesinde yardımcı olup olmayacağını değerlendirmeyi amaçladık . Yöntem: Otuz beş yaşından önce tip 2 diyabet tanısı almış hastalar çalışmaya alındı. Hastaların geriye dönük dosyaları incelenerek antropometrik özellikleri, tanı anında aldıkları tedaviler ve güncel tedavileri kaydedildi. Tip 1 diyabet tanılı veya pankreasa yönelik otoantikorları pozitif olan hastalar dışlandı. Hastalarda MPC kullanılarak MODY olma olasılığı hesaplandı. Bulgular: Çalışmada incelenen 72 hastanın (%40’ı kadın), yaş ortalaması 41,5±7,2 yıldı. Hastaların 18’ine (%25) tanı anında insülin başlanmıştı. Hastaların ortalama HbA1c değerleri %8,6±2,2, ortalama C-peptidleri ise 2,35±1,52 ng/dl idi. Hastaların MPC ile hesaplanan risklerinde ortalama MODY pozitif predikte edici değeri %11,23 idi. Riski ≤%20 olan 61 (%84.7), %20-50 arasında olan 9 (%12.5), ≥50% olan 2 (%2.8) hasta mevcuttu. MODY PPV skoru >%20 olan grupta, diyabet başlangıç yaşı ve vücut kitle indeksi diğerlerine göre anlamlı derecede düşüktü (her ikisi için de p

🔖

Cite This Article

OĞUZ, A., ERBAKAN, A. N., KESKİNLER, M. V. (2022). MODY Probability Ratios in Patients Diagnosed with Type 2 Diabetes Mellitus at a Young Age. Medeniyet Medical Journal, Cilt: 35 - Sayı: 4, 290–294. https://ajindex.com/articles/579212

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Tattersall RB, Fajans SS. A difference between the inheritance of classical juvenile-onset and maturity-onset type diabetes of young people. Diabetes. 1975;24:44-53. [CrossRef] 2. Gat-Yablonski G, Shalitin S, Phillip M. Maturity onset diabetes of the young--review. Pediatr Endocrinol Rev. 2006;Suppl 3:514-20. 3. McDonald TJ, Colclough K, Brown R, et al. Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type 1 diabetes. Diabet Med. 2011;28:1028-33. [CrossRef] 4. Thanabalasingham G, Owen KR. Diagnosis and management of maturity onset diabetes of the young (MODY). BMJ. 2011;343:d6044. [CrossRef] 5. Dussoix P, Vaxillaire M, Iynedjian PB, et al. Diagnostic heterogeneity of diabetes in lean young adults: classification based on immunological and genetic parameters. Diabetes. 1997;46:622-31. [CrossRef] 6. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med. 2001;345:971-80. [CrossRef] 7. Ellard S, Bellanné-Chantelot C, Hattersley AT; European Molecular Genetics Quality Network (EMQN) MODY group. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia. 2008;51:546-53. [CrossRef] 8. Shields BM, McDonald TJ, Ellard S, Campbell MJ, Hyde C, Hattersley AT. The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes. Diabetologia. 2012;55:1265-72. [CrossRef] 9. Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia. 2010;53:2504-8. [CrossRef] 10. Thanabalasingham G, Pal A, Selwood MP, et al. Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young. Diabetes Care. 2012;35:1206-12. [CrossRef] 11. Besser RE, Shepherd MH, McDonald TJ, et al. Urinary Cpeptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes. Diabetes Care. 2011;34:286-91. [CrossRef] 12. Tarantino RM, Abreu GM, Fonseca ACP, et al. MODY probability calculator for GCK and HNF1A screening in a multiethnic background population. Arch Endocrinol Metab. 2020;64:17-23. [CrossRef]